13 Avenue Morane Saulnier
Vélizy-Villacoublay 78140
France
33 1 39 46 51 04
https://www.novacyt.com
Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 120
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Mr. Steve Gibson | CFO & Director | N/A | N/A | N/A |
Bryan Close | Chief Operations Officer | N/A | N/A | N/A |
Ms. Mandy Cowling | Corporate & Investor Relations Manager | N/A | N/A | N/A |
Mr. David Franks | Chief Human Resources Officer | N/A | N/A | N/A |
Paul Oladimeji | Group Head of R&D | N/A | N/A | N/A |
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
Novacyt S.A.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 4. Die grundlegenden Scores sind Audit: 10, Vorstand: 5, Shareholderrechte: 6, Kompensation: 4.